These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32542437)

  • 21. Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells.
    Parmigiani E; Ivanek R; Rolando C; Hafen K; Turchinovich G; Lehmann FM; Gerber A; Brkic S; Frank S; Meyer SC; Wakimoto H; Günel M; Louvi A; Mariani L; Finke D; Holländer G; Hutter G; Tussiwand R; Taylor V; Giachino C
    Dev Cell; 2022 Aug; 57(15):1847-1865.e9. PubMed ID: 35803280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
    Miyazaki T; Ishikawa E; Sugii N; Matsuda M
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.
    Bloch O; Crane CA; Kaur R; Safaee M; Rutkowski MJ; Parsa AT
    Clin Cancer Res; 2013 Jun; 19(12):3165-75. PubMed ID: 23613317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma.
    Mieczkowski J; Kocyk M; Nauman P; Gabrusiewicz K; Sielska M; Przanowski P; Maleszewska M; Rajan WD; Pszczolkowska D; Tykocki T; Grajkowska W; Kotulska K; Roszkowski M; Kostkiewicz B; Kaminska B
    Oncotarget; 2015 Oct; 6(32):33077-90. PubMed ID: 26427514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
    Najem H; Khasraw M; Heimberger AB
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy: a promising approach for glioma treatment.
    Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
    Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
    Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid-derived suppressor cells in gliomas.
    Gieryng A; Kaminska B
    Contemp Oncol (Pozn); 2016; 20(5):345-351. PubMed ID: 28373814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour-derived CSF2/granulocyte macrophage colony stimulating factor controls myeloid cell accumulation and progression of gliomas.
    Sielska M; Przanowski P; Pasierbińska M; Wojnicki K; Poleszak K; Wojtas B; Grzeganek D; Ellert-Miklaszewska A; Ku MC; Kettenmann H; Kaminska B
    Br J Cancer; 2020 Aug; 123(3):438-448. PubMed ID: 32390004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
    Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
    CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.
    Miftah H; Naji O; Ssi SA; Ghouzlani A; Lakhdar A; Badou A
    Front Immunol; 2023; 14():1139268. PubMed ID: 37575237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
    Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
    J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
    Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS
    Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
    Lin GL; Nagaraja S; Filbin MG; Suvà ML; Vogel H; Monje M
    Acta Neuropathol Commun; 2018 Jun; 6(1):51. PubMed ID: 29954445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.